Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Vaccines
Research reports from Fred Hutchinson Cancer Research Center provide new insights into HIV/AIDS vaccines
October 14th, 2008
Research findings, 'On modeling the effects of T-cell vaccines on HIV acquisition and disease,' are discussed in a new report. According to recent research from the United States, "A 'T-cell vaccine' aims at generating cytotoxic T-lymphocytes (CTLs; the so-called 'killer' T-cells) rather than antibodies (as for traditional vaccines). The first (phase IIb) trials of this concept against HIV/AIDS began in 2004." "What can mechanistic modeling contribute to understanding the biological action of this class of vaccines, if any' Models are appropriate in any discussion of three potential vaccine effects: on acquisition of infection; on state of disease ('viral load', VL)...
Source: Cancer Weekly (2008-10-14)
|
